Nader Sanai

Sep 23, 2024 | cancernetwork.com | Nader Sanai

In a conversation with CancerNetwork®, Nader Sanai, MD discussed the current state of the glioblastoma field, highlighting ongoing research efforts to help improve outcomes among patients with this disease. Sanai is the director of the Ivy Brain Tumor Center and J.N Harber Professor of Neurological Surgery, Francis and Dionne Najafi chair for Neurosurgical Oncology, and chief of neurological oncology at Barrow Neurological Institute.

Sep 5, 2024 | cancernetwork.com | Nader Sanai

Nader Sanai, MD, spoke with CancerNetwork® about potential ongoing efforts that may advance the neuro-oncology field and improve outcomes among patients with glioblastoma and other diseases.

Sep 4, 2024 | cancernetwork.com | Nader Sanai

In a conversation with CancerNetwork®, Nader Sanai, MD, discussed how the assessment of niraparib (Zejula) in the phase 3 Gliofocus trial (NCT06388733) may lead to “meaningful” outcomes among patients with newly diagnosed unmethylated MGMT glioblastoma.

Sep 3, 2024 | cancernetwork.com | Nader Sanai

CancerNetwork® spoke with Nader Sanai, MD, about plans to evaluate treatment with niraparib (Zejula) vs temozolomide (Temodar) among patients with newly diagnosed MGMT unmethylated glioblastoma as part of the phase 3 Gliofocus study (NCT06388733).1 Specifically, Sanai, director of the Ivy Brain Tumor Center and J.N Harber Professor of Neurological Surgery, Francis and Dionne Najafi chair for Neurosurgical Oncology, and chief of neurological oncology at Barrow Neurological Institute,...

Jun 14, 2024 | onclive.com | Nader Sanai

CommentaryVideoJune 14, 2024Author(s):Nader Sanai, MD, discusses a phase 1 trial investigating BDTX-1535 in patients with recurrent, EGFR-mutated high-grade glioblastoma. Nader Sanai, MD, chief, Neurosurgical Oncology, director, Ivy Brain Tumor Center, Barrow Neurological Institute, discusses a phase 0/1 trial (NCT06072586) investigating BDTX-1535 in patients with recurrent, EGFR-mutated high-grade glioblastoma.